https://charts.traderzeitung.de/phases/US52635N1037
string(1435) "{"isin":"US52635N1037","name":"LENZ Therapeutics Inc","stock_id_xnas":42197143,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.072,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.125,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":1.3016},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":4.13,"close_at":"2026-09-23 01:39:00","complete":true,"perf_pct":0.1212}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":3.75,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-9.201},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":3.8,"close_at":"2026-09-23 23:16:00","complete":false,"perf_pct":1.3333}]}]}"
LENZ Therapeutics Aktie News & Nachrichten
Trading-Room

LENZ Therapeutics Aktie News & Nachrichten

[WKN: A407W6 | Symbol: LENZ]
Realtimekurs
   
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

LENZ Therapeutics

TOP-5-Kursziele der Analysten am 14.04.25

Deutsche Bank [DE0005140008]: Goldman Sachs adjustiert das Kursziel von 28,40 auf 27,75 Euro, bekräftigt...

TOP-5-Kursziele der Analysten am 18.03.25

SES S.A. [LU0088087324]: Bernstein bekräftigt Outperform-Rating und erhöht das Kursziel von 4,60 auf...

  • ‹
  • 1
  • ›
LENZ Therapeutics Nachrichtenticker öffnen
MT Newswires 08.06.2026 10:03 Uhr

LENZ Therapeutics erhält VIZZ-Zahlungen aus dem Everest-Corxel-Geschäft

04:01 AM EDT, 06/08/2026 (MT Newswires) -- LENZ Therapeutics (LENZ) teilte am Sonntag mit, dass das in Hongkong gelistete Unternehmen Everest Medicine